There is provided novel pyrimidine derivatives of formula (I)
or pharmaceutically acceptable salts thereof, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
A versatile route to 3-(pyrimidin-4-yl)-imidazo[1,2-a]pyridines and 3-(pyrimidin-4-yl)-pyrazolo[1,5-a]pyridines
作者:Richard Ducray、Pascal Boutron、Myriam Didelot、Hervé Germain、Franck Lach、Maryannick Lamorlette、Antoine Legriffon、Mickael Maudet、Morgan Ménard、Georges Pasquet、Fabrice Renaud、Iain Simpson、Gail L. Young
DOI:10.1016/j.tetlet.2010.07.024
日期:2010.9
A two-step synthesis of 3-(2-chloropyrimidin-4-yl)imidazo[1,2-a]pyridines is presented. The late stage elaboration of the imidazopyridine through a cyclocondensation allows a rapid access to a variety of substitution patterns. The intermediate enol ethers were obtained from inexpensive reagents in a ligand-free Heck coupling. This methodology has been extended to the formation of pyrazolo[1,5-a]pyridines via a formal 1,3-dipolar cycloaddition. (C) 2010 Elsevier Ltd. All rights reserved.
[EN] PYRAZOLO- AND IMIDAZOPYRIDINYLPYRIMIDINEAMINES AS IGF-1R TYROSINE KINASE INHIBITORS<br/>[FR] PYRAZOLO ET IMIDAZO-PYRIDINYL-PYRIMIDINAMINES UTILISÉS COMME INHIBITEURS DE LA TYROSINE KINASE IGF-1R
申请人:ASTRAZENECA AB
公开号:WO2010049731A1
公开(公告)日:2010-05-06
There is provided novel pyrimidine derivatives of formula (I) or pharmaceutically acceptable salts thereof, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.